NEW YORK (Reuters) - Shares of Mylan NV are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment.
Mylan shares languish at low valuation as EpiPen hearing nears
Reviewed by David
on
September 20, 2016
Rating: 5
No comments